These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 36631717)

  • 41. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.
    Li M; Sun F; Bi X; Lin Y; Yang L; Lu Y; Zhang L; Wan G; Yi W; Zhao L; Xie Y
    Virol Sin; 2022 Jun; 37(3):390-397. PubMed ID: 35257963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transforming growth factor-β: An early predictor of a functional cure in chronic hepatitis B treated with interferon.
    Wu LL; Li XY; Deng H; Xie DY; Gu YR; Bi YH; Huang YH; Gao ZL
    Virus Res; 2022 Feb; 309():198657. PubMed ID: 34919970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong CH; Lim SG
    Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.
    Liu J; Wang T; Zhang W; Cheng Y; He Q; Wang FS
    Hepatol Int; 2020 Dec; 14(6):958-972. PubMed ID: 33185803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
    Li MH; Yi W; Zhang L; Lu Y; Lu HH; Shen G; Wu SL; Hao HX; Gao YJ; Chang M; Liu RY; Hu LP; Cao WH; Chen QQ; Li JN; Wan G; Xie Y
    J Viral Hepat; 2019 Jul; 26 Suppl 1():32-41. PubMed ID: 31380582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel orally available small molecule that inhibits hepatitis B virus expression.
    Mueller H; Wildum S; Luangsay S; Walther J; Lopez A; Tropberger P; Ottaviani G; Lu W; Parrott NJ; Zhang JD; Schmucki R; Racek T; Hoflack JC; Kueng E; Point F; Zhou X; Steiner G; Lütgehetmann M; Rapp G; Volz T; Dandri M; Yang S; Young JAT; Javanbakht H
    J Hepatol; 2018 Mar; 68(3):412-420. PubMed ID: 29079285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
    Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
    J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.
    Wang CC; Tseng TC; Wang PC; Lin HH; Kao JH
    J Formos Med Assoc; 2014 Nov; 113(11):786-93. PubMed ID: 23911291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
    Buti M; Riveiro-Barciela M; Rodríguez-Frías F; Tabernero D; Esteban R
    Semin Liver Dis; 2020 Feb; 40(1):49-60. PubMed ID: 31805583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
    Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
    Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.